Layoffs Loom as Takeda Trims Early-Stage Efforts in AAV Gene Therapy, Rare Hematology

Takeda has moved away from early-stage R&D work in adeno-associated virus-based gene therapies and the rare hematology spaces, with an unknown number of employees set to “transition out” of the pharma.